The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 15, 2019

Filed:

Apr. 01, 2016
Applicant:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Inventors:

Yao-Ling Qiu, Andover, MA (US);

Hui Cao, Belmont, MA (US);

Wei Li, Lexington, MA (US);

Jorden Kass, Belmont, MA (US);

Xuri Gao, Newton, MA (US);

Xiaowen Peng, Sudbury, MA (US);

Meizhong Jin, Wellesley, MA (US);

Yat Sun Or, Watertown, MA (US);

Assignee:

Enanta Pharmaceuticals, Inc., Watertown, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 233/64 (2006.01); C07D 401/12 (2006.01); C07F 7/18 (2006.01); A61K 31/4164 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/553 (2006.01); A61K 31/695 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07F 9/6558 (2006.01); A61K 31/4178 (2006.01); A61K 31/661 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01); A61K 31/4164 (2013.01); A61K 31/4178 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/553 (2013.01); A61K 31/661 (2013.01); A61K 31/695 (2013.01); A61K 45/06 (2013.01); C07D 233/64 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07F 7/1804 (2013.01); C07F 9/65583 (2013.01);
Abstract

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A-Y—Z-L-R  (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.


Find Patent Forward Citations

Loading…